•  
  •  
  •  
  •  

2025-10-13 20:28:29

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mechanical Completion of OIL's Numaligarh-Siliguri Product Pipeline
  • HCL Technologies Limited declares interim dividend of Rs. 12
  • Anand Rathi Wealth Limited declares 1st interim dividend of Rs. 6
  • Tiger Logistics and Russia's H2 Invest signs MoU to bring cutting edge cryogenic technology to India for transportation of liquid hydrogen
  • Signature Global Recognized for ESG Commitment in GRESB Debut

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Coral Laboratories Ltd announces capacity expansion of Ointment Manufacturing
  • Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
  • Fredun Pharmaceuticals Ltd launches India's First Pure Jain Dog Biscuit
  • Lupin gets one observation from USFDA for Somerset, New Jersey manufacturing facility
  • Emcure Pharmaceuticals Ltd completes surveillance inspection by USFDA without any observation
  • Jubilant HollisterStier LLC launches New High-Speed Isolator based Line, at its Spokane Manufacturing Facility in the US
  • Legal update regarding Risdiplam - Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal
  • Fredun Pharmaceuticals Acquires Wagr.ai
  • Lupin unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
  • Shukra Pharmaceuticals Ltd receives order from Meril Healthcare Pvt Ltd
  • Sai Life Sciences, Agility Life Sciences, and Centrix Pharma announce an 'Integrated CMC Partnership' to accelerate drug development for innovators
  • Concord Biotech Ltd completes NAFDAC inspection successfully
  • Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
  • Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL
  • Shilpa Medicare Ltd allots 9,77,90,908 Bonus Equity shares
  • FDC Ltd receives USFDA approval for ANDA Pilocarpine Hydrochloride Ophthalmic Solutions
  • AstraZeneca Pharma India Ltd receives sale and distribution approval from CDSCO for Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder
  • Lupin Launches Liraglutide Injection in the United States
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Veerhealth Care Limited receives order for Hair Care and Oral Care products
  • Lupin Launches Rivaroxaban for Oral Suspension in the United States
  • Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime for Treatment of Serious GramNegative Infections
  • Lupin receives approval from U.S. FDA for Rivaroxaban for Oral Suspension

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • Mechanical Completion of OIL's Numaligarh-Siliguri Product Pipeline
  • HCL Technologies Limited declares interim dividend of Rs. 12
  • Anand Rathi Wealth Limited declares 1st interim dividend of Rs. 6
  • Tiger Logistics and Russia's H2 Invest signs MoU to bring cutting edge cryogenic technology to India for transportation of liquid hydrogen
  • Signature Global Recognized for ESG Commitment in GRESB Debut


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024